Growth and Future of Pharmacovigilance

The growth of pharmacovigilance reflects its increasingly important role in protecting patients by monitoring the safety of medicines throughout their lifecycle. As pharmaceutical development expands, regulatory requirements evolve and larger volumes of safety information become available, effective pharmacovigilance continues to become more important.

The development of new therapies, increasing use of medicines worldwide, expanding sources of real-world safety data and advances in technology are creating greater demand for robust systems capable of detecting, evaluating and managing medicine-related risks.

What Is Driving the Growth of Pharmacovigilance?

The growth of pharmacovigilance is influenced by several interconnected factors across pharmaceutical development, regulation, healthcare and technology.

These include:

• Continued development and approval of new medicines
• Increasing complexity of medicinal products
• Greater regulatory oversight of medicine safety
• Expansion of clinical research
• Increased volumes of adverse-event information
• Greater use of real-world data
• Increasing patient involvement in safety reporting
• Globalisation of pharmaceutical development and distribution
• Growth of digital health information
• Advances in pharmacovigilance technology

Together, these developments increase both the amount of safety information available and the need for effective evaluation of that information.

Increasing Focus on Patient Safety

The fundamental purpose of pharmacovigilance is to support the safe and appropriate use of medicines.

Safety information available at the time of initial marketing authorisation may be limited by factors such as the size and duration of clinical trials and the characteristics of the populations studied.

After a medicine enters wider use, additional information may become available about:

• Rare adverse reactions
• Long-term effects
• Use in broader patient populations
• Drug interactions
• Medication errors
• Use in special populations
• Previously unidentified safety concerns

Continuous safety surveillance is therefore necessary throughout the product lifecycle.

Regulatory Drivers of Pharmacovigilance Growth

Regulatory authorities require pharmaceutical companies and other responsible organisations to maintain systems for collecting, evaluating and reporting safety information.

Pharmacovigilance activities can include:

• Individual Case Safety Report management
• Expedited safety reporting
• Signal detection and management
• Periodic and aggregate safety reporting
• Risk management
• Post-authorisation safety activities
• Literature surveillance
• Benefit-risk evaluation

As pharmaceutical products are developed and marketed internationally, organisations must also manage requirements across multiple regulatory jurisdictions.

Growth of Safety Data

The volume and diversity of information potentially relevant to medicine safety continue to increase.

Safety data may originate from:

• Clinical trials
• Spontaneous adverse-event reports
• Healthcare professionals
• Patients and consumers
• Scientific literature
• Patient-support programmes
• Observational studies
• Registries
• Electronic healthcare information
• Digital channels
• Other post-marketing sources

Managing these diverse sources requires appropriate processes, trained personnel and pharmacovigilance technology.

Real-World Data and Pharmacovigilance

Real-world data can contribute to understanding the safety of medicines under routine conditions of use.

Potential sources include:

• Electronic health records
• Healthcare claims
• Patient registries
• Observational studies
• Patient-generated information
• Digital health technologies

When appropriate methodologies are applied, these data can support signal evaluation, risk characterisation and other post-authorisation safety activities.

The usefulness of real-world information depends on factors such as data quality, completeness, relevance and the methods used for analysis.

Technology Driving the Growth of Pharmacovigilance

Pharmacovigilance organisations increasingly use technology to manage large volumes of safety information and complex regulatory workflows.

Technology platforms can support:

• Safety case management
• Medical coding
• Regulatory reporting
• Literature surveillance
• Signal detection
• Aggregate reporting
• Workflow management
• Data analysis
• Quality control

Automation and artificial intelligence are also being explored and implemented for selected activities such as case intake, data extraction, duplicate detection, literature screening and analytical support.

These technologies can improve efficiency, but regulated pharmacovigilance activities continue to require appropriate governance, validation, quality controls and human oversight.

Increasing Importance of Signal Management

As safety datasets become larger and more diverse, effective signal detection and management becomes increasingly important.

Potential safety signals may arise from multiple sources and require scientific and medical evaluation to determine whether further investigation or regulatory action is necessary.

Signal management can involve:

• Signal detection
• Validation
• Confirmation
• Analysis and prioritisation
• Assessment
• Recommendations for action
• Communication
• Tracking of outcomes

Advanced analytical tools can support this process, but interpretation of potential safety issues continues to require appropriate clinical and scientific judgement.

Benefit-Risk Evaluation and Risk Management

Modern pharmacovigilance is not limited to collecting adverse-event reports.

Safety information must be considered alongside the known benefits of a medicinal product to support continuing assessment of its benefit-risk balance.

Depending on the product and regulatory requirements, risk-management activities may include:

• Identification of important risks
• Characterisation of safety concerns
• Additional pharmacovigilance activities
• Risk-minimisation measures
• Evaluation of risk-minimisation effectiveness
• Periodic benefit-risk assessment

This lifecycle approach increases the importance of pharmacovigilance well beyond initial regulatory approval.

Globalisation of Pharmacovigilance

Medicinal products are frequently developed and marketed across multiple countries.

Global pharmaceutical organisations therefore need systems capable of managing:

• Local and international safety requirements
• Different regulatory reporting timelines
• Global and local safety information
• Standardised medical terminology
• Electronic safety-data exchange
• Affiliate and partner responsibilities
• Regulatory authority communications

International harmonisation helps establish common standards, but important differences between national and regional requirements remain.

International medicine-safety monitoring is also supported through the WHO Programme for International Drug Monitoring, which facilitates international collaboration in pharmacovigilance and the identification of medicine-safety concerns.

Patient Involvement

Patients and consumers have an increasingly important role in medicine-safety surveillance.

Patient reports can provide valuable information about:

• Experiences of adverse reactions
• Impact on quality of life
• Treatment burden
• Medication use
• Outcomes that may not otherwise be captured

Patient perspectives can complement information received from healthcare professionals, clinical studies and other safety-data sources.

Growth of Pharmacovigilance and Professional Skills

The growth of pharmacovigilance and the expanding scope of medicine-safety activities create a continuing need for professionals with appropriate pharmacovigilance knowledge and technical skills.

Roles can involve areas such as:

• ICSR processing
• Medical review
• Safety database operations
• Quality assurance
• Aggregate reporting
• Signal management
• Risk management
• Regulatory compliance
• Safety analytics
• Pharmacovigilance systems

As technology becomes more integrated into safety operations, knowledge of pharmacovigilance processes, regulations, safety systems and data interpretation is increasingly valuable.

Professionals seeking structured training for roles in drug safety can explore ClinSkill’s Diploma in Pharmacovigilance, covering core pharmacovigilance concepts, safety reporting, regulatory requirements and related drug-safety processes.

Career Development in Pharmacovigilance

Pharmacovigilance is multidisciplinary and can involve professionals with backgrounds in pharmacy, medicine, life sciences, clinical research, regulatory affairs and related disciplines.

Career development may progress from operational safety activities toward specialised or leadership responsibilities in areas such as:

• Case management
• Medical safety
• Signal management
• Aggregate reporting
• Risk management
• Pharmacovigilance quality
• Safety systems
• Regulatory strategy
• Safety operations

Practical understanding of both pharmacovigilance principles and the technologies used to manage safety information can strengthen professional capabilities.

Future Growth of Pharmacovigilance

The future of pharmacovigilance is likely to involve increasing integration of real-world data, automation, artificial intelligence, advanced analytics and interconnected safety systems.

At the same time, the core responsibilities of pharmacovigilance remain unchanged: identifying potential medicine-related risks, evaluating safety information, supporting appropriate risk management and contributing to informed benefit-risk decisions.

As medicines, data sources and technologies continue to evolve, pharmacovigilance will remain an essential component of pharmaceutical development and post-marketing patient safety.

You may be interested in…